Publications by authors named "Yingsong Mu"

Chronic kidney disease (CKD) is a global public health problem, involving about 10% of the global population. Unfortunately, there are currently no effective drugs. Kidney fibrosis is the main pathology of CKD, where integrins play crucial roles in renal fibrogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • * The study used various experiments to explore the relationship between the gut's microbiome and renal fibrosis, identifying metabolite changes and testing these connections through molecular and cellular techniques.
  • * Xylitol, a natural intestinal metabolite, has been shown to delay renal injury and fibrosis by inhibiting the BRD4 protein and its related TGF-β pathway, highlighting its therapeutic potential in managing renal fibrosis.
View Article and Find Full Text PDF

Sepsis is a systemic inflammatory response to infection, where sepsis-associated acute kidney injury (AKI) is a common morbid disease with a high morbidity and mortality, and however at present no effective therapy exists. Increasing evidence have shown that mitochondrial damage and inflammatory response are important initiating factors in pathogenesis of septic AKI. Natural flavonoid pectolinarigenin exerted anti-inflammatory properties in previous studies, while its role in septic AKI remains unknown.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Yingsong Mu"

  • - Yingsong Mu's research primarily focuses on renal diseases, particularly chronic kidney disease (CKD) and its progression to renal fibrosis, addressing the urgent need for effective therapies in these areas.
  • - Recent studies include the exploration of dual integrin inhibitors like Bexotegrast, which show promise in ameliorating organ injury and fibrogenesis in fibrotic kidney disease, highlighting the mechanistic role of integrins in renal pathology.
  • - Additionally, Mu's work investigates the gut-kidney axis, demonstrating how natural metabolites like xylitol can lower BRD4 levels to mitigate renal fibrosis, as well as exploring the protective effects of pectolinarigenin against septic acute kidney injury through targeting inflammatory and mitochondrial dysfunction pathways.